natgillin/translations-raw huggingface dataset:
If you are using insulin, your doctor will tell you how to reduce the dose of insulin and will recommend you to monitor your blood sugar more frequently, in order to avoid hyperglycaemia (high blood sugar) and diabetic ketoacidosis (a complication of diabetes that occurs when the body is unable to break down glucose because there is not enough insulin). 
Če uporabljate insulin, vam bo zdravnik povedal, kako zmanjšate odmerek insulina, in priporočil pogostejše spremljanje sladkorja, da s tem preprečite pojav hiperglikemije (visoka raven sladkorja v krvi) in diabetične ketoacidoze (zaplet pri sladkorni bolezni, ki nastopi, ko telo zaradi pomanjkanja insulina ni sposobno razgraditi glukoze).
The dose of immediate-release exenatide does not need to be adjusted on a day-by-day basis depending on self-monitored glycaemia. 
V odvisnosti od bolnikovega nadzora glikemije odmerka Odmerka eksenatida v obliki s takojšnjim sproščanjem dnevno ni treba prilagajati glede na bolnikov samonadzor glikemije.
Blood glucose selfmonitoring may be necessary to adjust the dose of sulphonylurea. 
Bolnikov nadzor glukoze v krvi je morda potreben za prilagoditev odmerka sulfonilsečnine.
Carbimazole must only be administered during pregnancy after a strict individual benefit/risk assessment and only at the lowest effective dose without additional administration of thyroid hormones. 
Karbimazol se sme med nosečnostjo lahko dajati samo po dosledni individualni oceni koristi in tveganja ter samo v najmanjšem učinkovitem odmerku, brez dodajanja tiroidnih hormonov.
Thiamazole must only be administered during pregnancy after a strict individual benefit/risk assessment and only at the lowest effective dose without additional administration of thyroid hormones. 
Tiamazol se sme med nosečnostjo dajati samo po dosledni individualni oceni koristi in tveganja ter samo v najmanjšem učinkovitem odmerku, brez dodajanja tiroidnih hormonov.
If carbimazole is used during pregnancy, the lowest effective dose without additional administration of thyroid hormones should be administered. 
Če se karbimazol uporablja med nosečnostjo, je treba dajati najmanjši učinkoviti odmerek, brez dodajanja tiroidnih hormonov.
If thiamazole is used during pregnancy, the lowest effective dose without additional administration of thyroid hormones should be administered. 
Če se tiamazol uporablja med nosečnostjo, je treba dajati najmanjši učinkoviti odmerek, brez dodajanja tiroidnih hormonov.
Trulicity is not an insulin and should therefore not be used as a substitute for insulin. 
Zdravilo Trulicity ni insulin in se zato ne sme uporabljati kot njegovo nadomestilo.
Close maternal, foetal and neonatal monitoring is warranted (see section 4.6). 
Upravičeno je skrbno spremljanje matere, ploda in novorojenčka (glejte poglavje 4.6).
However, blood glucose self-monitoring may become necessary to adjust the dose of sulphonylureas or the dose of basal insulin. 
Vendar lahko postane bolnikov nadzor glukoze v krvi potreben za prilagoditev odmerka sulfonilsečnin ali odmerka bazalnega insulina.
Prolonged-release exenatide is not a substitute for insulin. 
Eksenatid v obliki s podaljšanim sproščanjem ni nadomestilo za insulin.
Thiamazole must not be given to patients with a history of acute pancreatitis after administration of thiamazole or its prodrug carbimazole. 
Tiamazol se ne sme dajati bolnikom z anamnezo akutnega pankreatitisa po dajanju tiamazola ali njegovega predzdravila karbimazola.
Carbimazole must not be given to patients with a history of acute pancreatitis after administration of carbimazole or its active metabolite thiamazole. 
Karbimazol se ne sme dajati bolnikom z anamnezo akutnega pankreatitisa po dajanju karbimazola ali njegovega aktivnega presnovka tiamazola.
Bydureon is not an insulin and should therefore not be used as a substitute for insulin. 
Zdravilo Bydureon ni insulin in se zato ne sme uporabljati kot njegovo nadomestilo.
There have been post-marketing reports of acute pancreatitis in patients receiving thiamazole or its prodrug carbimazole. 
Po začetku trženja so poročali o akutnem pankreatitisu pri bolnikih, ki so prejemali tiamazol ali njegovo predzdravilo karbimazol.
There have been post-marketing reports of acute pancreatitis in patients receiving carbimazole or its active metabolite thiamazole. 
Po začetku trženja so poročali o akutnem pankreatitisu pri bolnikih, ki so prejemali karbimazol ali njegov aktivni presnovek tiamazol.
Not known (frequency cannot be estimated from the available data) …inflammation of the pancreas (acute pancreatitis). 
Neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
Patients with a history of acute pancreatitis after administration of carbimazole or its active metabolite thiamazole. 
Bolniki z anamnezo akutnega pankreatitisa po dajanju karbimazola ali njegovega aktivnega presnovka tiamazola.
Patients with a history of acute pancreatitis after administration of thiamazole or its prodrug carbimazole. 
Bolniki z anamnezo akutnega pankreatitisa po dajanju tiamazola ali njegovega predzdravila karbimazola.
Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea or insulin, particularly when Trulicity therapy is started and insulin is reduced. 
Samokontrola glukoze v krvi pa je potrebna za prilagajanje odmerka sulfonilsečnine ali insulina, zlasti ob začetku zdravljenja z zdravilom Trulicity in zmanjšanju odmerka insulina.
Posology and method of administration Add-on therapy 
Odmerjanje in način uporabe Dodatno zdravljenje
Blood glucose selfmonitoring is necessary to adjust the dose of sulphonylurea or insulin, particularly when Byetta therapy is started and insulin is reduced. 
Bolnikov samonadzor glukoze v krvi pa je potreben za prilagajanje odmerka sulfonilsečnine ali insulina, zlasti ob začetku zdravljenja z zdravilom Byetta in zmanjšanju odmerka insulina.
Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea and insulin, particularly when Victoza therapy is started and insulin is reduced. 
Samokontrola glukoze v krvi pa je potrebna za prilagajanje odmerka sulfonilsečnine in insulina, zlasti ob začetku zdravljenja z zdravilom Victoza in zmanjšanju odmerka insulina.
Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea and of insulin particularly when prolonged-release exenatide therapy is started and insulin is reduced. 
Bolnikov samonadzor glukoze v krvi pa je potreben za prilagajanje odmerka sulfonilsečnine in insulina, zlasti ob začetku zdravljenja z eksenatidom v obliki s podaljšanim sproščanjem in zmanjšanju odmerka insulina.
What you need to know before you take <medicinal product> Warnings and precautions <Medicinal product> can cause harm to an unborn baby. 
Kaj morate vedeti, preden boste vzeli zdravilo <ime zdravila> Opozorila in previdnostni ukrepi
Strength Pharmaceutical Form Route of Administration Packaging 
Jakost Farmacevtska oblika Pot uporabe
Name 
ime
Immediate Packaging Pack size 
Pot uporabe Stična ovojnina Velikost pakiranja plastenka (HDPE)
The European Commission granted a marketing authorisation valid throughout the European Union for Celsentri on 18 September 2007. 
Evropska komisija je dovoljenje za promet z zdravilom Celsentri, veljavno po vsej Evropski uniji, izdala 18. septembra 2007.
What measures are being taken to ensure the safe and effective use of Celsentri? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Celsentri?
The full EPAR for Celsentri can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Celsentri je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Other information about Celsentri 
Druge informacije o zdravilu Celsentri
The safety profile of Celsentri is considered acceptable and no major concerns have been identified. 
Varnostni profil zdravila Celsentri je bil ocenjen kot sprejemljiv, saj ni bilo ugotovljenih nobenih večjih zadržkov.
In adults, the recommended dose is 150, 300 or 600 mg twice a day, depending on the other medicines that the patient is taking. 
Priporočeni odmerek pri odraslih je 150, 300 ali 600 mg dvakrat na dan, odvisno od drugega zdravila, ki ga bolnik jemlje.
What is Celsentri and what is it used for? 
Kaj je zdravilo Celsentri in za kaj se uporablja?
Celsentri is available as tablets (25, 75, 150 and 300 mg) and as a liquid (20 mg/ml) to be taken by mouth. 
Zdravilo Celsentri je na voljo v obliki tablet (25, 75, 150 in 300 mg) in tekočine (20 mg/ml) za peroralno uporabo.
Based on these data, effectiveness is expected to be similar in children and adults. 
Na podlagi teh podatkov je mogoče pričakovati, da je učinkovitost zdravila pri otrocih in odraslih podobna.
The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Celsentri's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Celsentri večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The patients had previously taken other treatments for HIV for at least six months, but these had stopped working. 
Bolniki so predhodno vsaj šest mesecev jemali druga zdravila za zdravljenje okužbe z virusom HIV, vendar so ta prenehala delovati.
It is not intended to provide practical advice on how to use Celsentri. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
This is a summary of the European public assessment report (EPAR) for Celsentri. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Celsentri.
Patients who have reduced kidney function may need to take Celsentri less frequently. 
Bolniki, ki imajo okrnjeno delovanje ledvic, bodo morda morali zdravilo Celsentri jemati manj pogosto.
What benefits of Celsentri have been shown in studies? 
Kakšne koristi je zdravilo Celsentri izkazalo v študijah?
Celsentri tablets must not be used in patients who are hypersensitive (allergic) to peanut and soya. 
Zdravila Celsentri v obliki tablet ne smejo uporabljati bolniki, ki so preobčutljivi za (alergični na) arašide in sojo.
Similar results were also seen when looking at the patients who continued treatment with Celsentri 300 mg twice a day for 48 weeks. 
Podobni rezultati so bili zabeleženi ob spremljanju bolnikov, ki so zdravljenje z zdravilom Celsentri v odmerku 300 mg dvakrat na dan nadaljevali še nadaljnjih 48 tednov.
What are the risks associated with Celsentri? 
Kakšna tveganja so povezana z zdravilom Celsentri?
Why is Celsentri approved? 
Zakaj je bilo zdravilo Celsentri odobreno?
In children, the dose is based on body weight. 
Pri otrocih je odmerek odvisen od telesne mase.
The most common side effects with Celsentri (which may affect up to 1 in 10 people) are nausea (feeling sick), diarrhoea, fatigue (tiredness) and headache. 
Najpogostejši neželeni učinki zdravila Celsentri (ki lahko prizadenejo največ 1 osebo od 10) so navzeja (slabost), driska, utrujenost in glavobol.
The active substance in Celsentri, maraviroc, is a ‘CCR5 antagonist'. 
Zdravilna učinkovina zdravila Celsentri, maravirok, je „antagonist CCR5“.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Celsentri have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Celsentri upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
All of the patients also took ‘optimised background therapy' (a combination of other HIV medicines chosen for each patient to increase the chances of reducing the levels of HIV in the blood). 
Vsi bolniki so sočasno prejemali „optimizirano osnovno terapijo“ (kombinacijo drugih zdravil za zdravljenje okužbe z virusom HIV, izbranih za vsakega posamičnega bolnika posebej zaradi povečanja možnosti znižanja ravni virusa HIV v krvi).
Celsentri does not cure HIV infection or AIDS, but it may hold off the damage to the immune system and the development of infections and diseases associated with AIDS. 
Zdravilo Celsentri ne ozdravi okužbe z virusom HIV ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter prepreči razvoj okužb in bolezni, povezanih z aidsom.
For more information about treatment with Celsentri, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Celsentri preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Celsentri has been shown to be effective at reducing the levels of HIV in the blood in two main studies involving a total of 1,076 mostly adult patients with CCR5-tropic HIV infection. 
Zdravilo Celsentri se je izkazalo za učinkovito pri zmanjševanju ravni virusa HIV v krvi v dveh glavnih študijah, v katerih je sodelovalo skupno 1 076 večinoma odraslih bolnikov, okuženih s CCR5tropnim HIV.
Celsentri is an HIV medicine used to treat patients from 2 years of age and weighing at least 10 kg who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). 
Celsentri je zdravilo proti okužbi z virusom HIV, ki se uporablja pri bolnikih, starejših od dveh let in s telesno maso vsaj 10 kg, ki so okuženi z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
This means that the virus, when infecting a cell, attaches to a specific protein called CCR5 on the surface of the cell. 
To pomeni, da se virus ob okužbi celice veže na posebno beljakovino, imenovano CCR5, ki se nahaja na površini celice.
As HIV can only reproduce itself within cells, Celsentri, taken in combination with other HIV medicines, reduces the level of CCR5-tropic HIV, and keeps it at a low level. 
Ker se virus HIV lahko razmnožuje samo znotraj celic, zdravilo Celsentri v kombinaciji z drugimi zdravili proti okužbi z virusom HIV zmanjšuje raven CCR5-tropnega HIV in jo ohranja na nizki ravni.
For practical information about using Celsentri, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Celsentri naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Additional data indicate that Celsentri given at a suitable dose to children is handled by their body in the same way as in adults. 
Dodatni podatki kažejo, da pri otrocih, ki prejemajo ustrezen odmerek zdravila Celsentri, telo enako presnavlja zdravilo kot pri odraslih.
Celsentri cannot work against viruses that attach to another protein called CXCR4, or when it can attach to both CCR5 and CXCR4. 
Zdravilo Celsentri ni učinkovito proti virusom, ki se vežejo na drugo beljakovino, imenovano CXCR4, ali na obe beljakovini, CCR5 in CXCR4.
Celsentri used in combination with other HIV medicines has been shown to be effective at reducing the levels of HIV in the blood in adults, and similar effects are expected in children. 
Uporaba zdravila Celsentri v kombinaciji z drugimi zdravili za zdravljenje okužbe z virusom HIV se je izkazala kot učinkovita pri zmanjševanju ravni virusa HIV v krvi pri odraslih, podoben učinek pa se pričakuje tudi pri otrocih.
Celsentri can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of HIV infection. 
Predpisovanje in izdaja zdravila Celsentri je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
CCR5-tropic HIV uses this protein to enter the cells. 
CCR5-tropni HIV s pomočjo te beljakovine vstopa v celico.
In the studies Celsentri was compared with placebo (a dummy treatment). 
V obeh študijah so zdravilo Celsentri primerjali s placebom (zdravilom brez zdravilne učinkovine).
Before treatment, the doctor must check that the patient's blood only shows infection with CCR5-tropic virus. 
Pred začetkom zdravljenja mora zdravnik preveriti, ali je v bolnikovi krvi prisoten le CCR5-tropni HIV.
It blocks the CCR5 protein on the surface of the cells in the body that HIV infects. 
Ta zavira beljakovino CCR5 na površini celic telesa, ki so okužene z virusom HIV.
Looking at the results of the two studies taken together, the levels of HIV in the blood had fallen by an average of 99% after 24 weeks in the patients adding Celsentri to optimised background therapy, compared with 90% in those adding placebo. 
Analiza rezultatov obeh študij je pokazala, da so ravni virusa HIV v krvi po 24 tednih padle za povprečno 99 % pri bolnikih, ki so kot dodatek k optimizirani osnovni terapiji jemali zdravilo Celsentri, medtem ko so pri bolnikih, ki so kot dodatek jemali placebo, ravni padle za 90 %.
Celsentri contains the active substance maraviroc. 
Zdravilo Celsentri vsebuje zdravilno učinkovino maravirok.
The proportion of patients who had undetectable levels of HIV in their blood after 24 weeks was about 45% with Celsentri compared to 23% with placebo. 
Delež bolnikov z nezaznavnimi ravnmi virusa HIV v krvi po 24 tednih je bil 45 % v skupini, ki je prejemala zdravilo Celsentri, in 23 % v skupini, ki je prejemala placebo.
For the full list of all side effects reported with Celsentri, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Celsentri, glejte navodilo za uporabo.
Celsentri is used in combination with other HIV medicines, and only in patients who have been treated for HIV infection before and only when the HIV-1 they are infected with is ‘CCR5-tropic', which is determined by a blood test. 
Zdravilo Celsentri se uporablja v kombinaciji z drugimi zdravili proti okužbi z virusom HIV, in sicer samo pri bolnikih, ki so predhodno že bili zdravljeni zaradi okužbe z virusom HIV in pri katerih je prisoten le CCR5-tropni HIV-1, kar se ugotavlja s krvnimi preiskavami.
How is Celsentri used? 
Kako se zdravilo Celsentri uporablja?
How does Celsentri work? 
Kako zdravilo Celsentri deluje?
By attaching itself to the protein, Celsentri prevents the virus from entering the cells. 
Zdravilo Celsentri z vezavo na to beljakovino preprečuje vstop virusa v celico.
The European Commission granted a marketing authorisation valid throughout the European Union for Aprovel on 27 August 1997. 
Evropska komisija je dovoljenje za promet z zdravilom Aprovel, veljavno po vsej Evropski uniji, odobrila 27. avgusta 1997.
Other information about Aprovel 
Druge informacije o zdravilu Aprovel
The full EPAR for Aprovel can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Aprovel je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Aprovel was used for two years or more. 
Bolniki so zdravilo Aprovel jemali dve leti ali več.
What benefit has Aprovel shown during the studies? 
Kakšne koristi je zdravilo Aprovel izkazalo med študijami?
The usual recommended dose of Aprovel is 150 mg once a day. 
Običajni priporočeni odmerek zdravila Aprovel znaša 150 mg enkrat dnevno.
This is a summary of the European public assessment report (EPAR) for Aprovel. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Aprovel.
If the blood pressure is not sufficiently controlled, the dose can be increased to 300 mg a day or other medicines for hypertension can be added, such as hydrochlorothiazide. 
Če krvni tlak ni zadostno nadzorovan, se odmerek lahko poveča na 300 mg dnevno ali dodajo druga zdravila za zdravljenje visokega krvnega tlaka, kot je npr. hidroklorotiazid.
For more information about treatment with Aprovel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Aprovel preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What is the risk associated with Aprovel? 
Kakšna tveganja so povezana z zdravilom Aprovel?
The CHMP decided that Aprovel's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Aprovel večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aprovel. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Aprovel, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
In this study, Aprovel was compared with placebo and with amlodipine. 
V tej študiji so zdravilo Aprovel primerjali s placebom in amlodipinom.
Aprovel is a medicine that contains the active substance irbesartan. 
Aprovel je zdravilo, ki vsebuje zdravilno učinkovino irbesartan.
For the treatment of kidney disease, Aprovel was studied in two large studies involving a total of 2,326 patients with type 2 diabetes. 
Zdravilo Aprovel so glede zdravljenja ledvičnega obolenja preučevali v okviru dveh velikih študij, ki sta vključevali skupno 2 326 bolnikov s sladkorno boleznijo tipa 2.
Aprovel is used in adults who have essential hypertension (high blood pressure). 
Zdravilo Aprovel se uporablja pri odraslih, ki imajo esencialno hipertenzijo (visok krvni tlak).
Aprovel must not be used in people who are hypersensitive (allergic) to irbesartan or any of the other ingredients. 
Zdravila Aprovel ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) irbesartan ali katero koli drugo sestavino zdravila.
The most common side effect with Aprovel (seen in more than 1 patient in 10) is hyperkalaemia (high blood potassium levels). 
Najpogostejši neželeni učinek zdravila Aprovel (opažen pri več kot 1 bolniku od 10) je hiperkaliemija (visoka raven kalija v krvi).
The active substance in Aprovel, irbesartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. 
Zdravilna učinkovina v zdravilu Aprovel, irbesartan, je antagonist receptorjev angiotenzina II, kar pomeni, da v telesu preprečuje delovanje hormona, imenovanega angiotenzin II.
Why has Aprovel been approved? 
Zakaj je bilo zdravilo Aprovel odobreno?
Aprovel was compared with placebo (a dummy treatment) in 712 patients and with other medicines for hypertension (atenolol, enalapril or amlodipine) in 823 patients. 
Zdravilo Aprovel so pri 712 bolnikih primerjali s placebom (zdravilom brez zdravilne učinkovine), pri 823 bolnikih pa z drugimi zdravili za zdravljenje visokega krvnega tlaka (atenololom, enalaprilom ali amlodipinom).
For the full list of all side effects reported with Aprovel, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Aprovel, glejte navodilo za uporabo.
Aprovel in combination with aliskirencontaining medicines (used to treat essential hypertension) must not be used in patients with diabetes, or moderate or severe kidney impairment. 
Zdravilo Aprovel se v kombinaciji z zdravili, ki vsebujejo aliskiren (ki se uporablja za zdravljenje esencialne hipertenzije), ne sme uporabljati pri bolnikih s sladkorno boleznijo ali zmerno do hudo ledvično okvaro.
In patients with hypertension and type 2 diabetes, Aprovel is added to some other treatments for hypertension. 
Pri bolnikih z visokim krvnim tlakom in sladkorno boleznijo tipa 2 se zdravilo Aprovel dodaja nekaterim drugim zdravilom za zdravljenje visokega krvnega tlaka.